reports
Navidea Biopharmaceuticals Announces Reverse Stock Split
DUBLIN, Ohio--(BUSINESS WIRE)-- Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that its Board of Directors has approved a one-for-twenty reverse stock split of its issued and outstanding shares of common stock. The reverse split will be effective at 12:01 a.m. (EDT) on April 26, 2019, and shares of the Company’s common stock will begin trading on a split-adjusted basis when the NYSE Am...
Navidea Biopharmaceuticals Receives FDA Feedback Regarding Rheumatoid ...
DUBLIN, Ohio--(BUSINESS WIRE)-- Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that it received feedback from the U.S Food and Drug Administration (“FDA”) regarding the Company’s planned clinical studies that will evaluate joint disease in patients with Rheumatoid Arthritis (“RA”) and monitor patient response to therapy. Clinical Studies in Rheumatoid Arthritis ...
Navidea Biopharmaceuticals Data to be Presented at Society of Nuclear ...
DUBLIN, Ohio--(BUSINESS WIRE)-- Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that Arash Kardan, M.D., will give an oral presentation on the results of the Company’s NAV3-21 clinical study at the Society of Nuclear Medicine and Molecular Imaging (“SNMMI”) Annual Meeting in June 2019. The presentation is titled “A Phase I/Phase II Study of Intravenously (“IV”) Administered Tc99m Tilman...
Navidea Biopharmaceuticals Announces Stock Purchase Agreement; Other B...
DUBLIN, Ohio--(BUSINESS WIRE)-- Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced execution of a Stock Purchase Agreement (the “Purchase Agreement”) with an existing investor, John K. Scott, Jr. (the “Investor”), pursuant to which the Company will issue to the Investor in a private placement (the “Private Placement”) up to $3.0 million in shares (the “Securities”) of the Company’s common ...
Navidea Biopharmaceuticals Reports Fourth Quarter and Full Year 2018 F...
DUBLIN, Ohio--(BUSINESS WIRE)-- Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced its financial results for the fourth quarter and full year of 2018. Navidea reported total revenues for the quarter of $119,000. Net loss attributable to common stockholders was $3.2 million. “Navidea had a productive quarter as we advanced the business and our novel imaging pipeline,” said Mr. Jed ...
Navidea Biopharmaceuticals Schedules Fourth Quarter 2018 Earnings Conf...
DUBLIN, Ohio--(BUSINESS WIRE)-- Navidea Biopharmaceuticals, Inc. (NYSE American:NAVB) (“Navidea” or “the Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced it will host a conference call on Thursday, March 7th, 2019, at 5:00 pm ET to discuss its financial results for the fourth quarter of 2018 in conjunction with the filing of its annual report on Form 10-K. Jed Latkin, Chief Executive Officer, and Erika Gibson, Director, Finance and Administration, of ...
Navidea Biopharmaceuticals Announces Extension of NYSE American Listin...
DUBLIN, Ohio--(BUSINESS WIRE)-- Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced the receipt of a notice from the NYSE American LLC (the “NYSE American”) on January 28, 2019 that the NYSE American has granted the Company an extension until March 31, 2019 to regain compliance with Section 1003(f)(v) of the NYSE American’s continued listing standards. Navidea previously disclosed ...
Navidea Biopharmaceuticals Announces Decision by Ohio Supreme Court
DUBLIN, Ohio--(BUSINESS WIRE)-- Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that the Ohio Supreme Court has dismissed a Petition filed by Capital Royalty Partners II, L.P. and affiliated entities. On August 27, 2018, Capital Royalty Partners II, L.P. and several affiliated entities ("CRG") filed a Petition with the Ohio Supreme Court seeking a Writ of Prohibition against th...
Navidea Biopharmaceuticals Announces Patent Extension for Lymphoseek®
DUBLIN, Ohio--(BUSINESS WIRE)-- Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that on November 23, 2018 the U.S. Food and Drug Administration (“FDA”) released a letter to the U.S. Patent and Trademark Office (“USPTO”) indicating that the USPTO is allowed to extend the patent duration of U.S. patent 6,409,990 for an additional 5 years or until May 12, 2025. This patent claims ...
Navidea Biopharmaceuticals Appoints Adam Cutler to Board of Directors
DUBLIN, Ohio--(BUSINESS WIRE)-- Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced the appointment of Adam Cutler to the Company’s board of directors, effective December 1, 2018. “We are pleased to welcome Mr. Cutler to Navidea’s board of directors,” said Mr. Jed A. Latkin, Chief Executive Officer of Navidea. “He will be a significant asset to the Company, as he has over 20 years ...
Navidea Biopharmaceuticals Appoints Dr. Michael Rosol as Chief Medical...
DUBLIN, Ohio--(BUSINESS WIRE)-- Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced the appointment of Michael Rosol, PhD as Chief Medical Officer of Navidea, effective December 17, 2018. Dr. Rosol brings to this position over 10 years of experience in biomedical imaging and commercialization. “We are pleased for Dr. Rosol to join Navidea and bring his deep insights into the needs ...
Navidea Biopharmaceuticals to Present at the 11th Annual LD Micro Even...
DUBLIN, Ohio--(BUSINESS WIRE)-- Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that its Chief Executive Officer, Jed Latkin, will present a corporate overview of the Company at the 11th Annual LD Micro Event, being held December 4-6, 2018 in Bel-Air, California. Presentation DetailsWhere: Luxe Sunset, Bel-Air, CaliforniaWhen: Thursday, December 6 at 9:00am PSTTrack: 3Live Webc...
Navidea Biopharmaceuticals Announces Presentation at the Radiological ...
DUBLIN, Ohio--(BUSINESS WIRE)-- Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that Dr. David Ralph, Director of Drug Development and IP Manager of Navidea, will be presenting at the RSNA 104th Scientific Assembly and Annual Meeting, which is taking place November 25-30, 2018 in Chicago, IL. The oral presentation will highlight an abstract evaluated and selected through...
Navidea Biopharmaceuticals Appoints Dr. Kathy Rouan to Board of Direct...
DUBLIN, Ohio--(BUSINESS WIRE)-- Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced the appointment of Kathy Rouan, PhD, to the Company’s board of directors, effective December 1, 2018. “We are excited for Dr. Rouan to join Navidea’s board of directors at an instrumental time in the Company’s development,” said Mr. Jed A. Latkin, Chief Executive Officer of Navidea. “Dr. Rouan is a ...
Navidea Biopharmaceuticals Reports Third Quarter 2018 Financial Result...
DUBLIN, Ohio--(BUSINESS WIRE)-- Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced its financial results for the third quarter of 2018. Navidea reported total revenues for the quarter of $231,000. Net loss attributable to common stockholders was $3.8 million. “Navidea had a productive quarter as we advanced the business and our novel imaging pipeline,” said Mr. Jed A. Latkin, Chie...
Navidea Biopharmaceuticals Schedules Third Quarter 2018 Earnings Confe...
DUBLIN, Ohio--(BUSINESS WIRE)-- Navidea Biopharmaceuticals, Inc. (NYSE American:NAVB) (“Navidea” or “the Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced it will host a conference call on Wednesday, November 7th, 2018, at 4:30 pm E.T. to discuss its financial results for the third quarter of 2018 in conjunction with the filing of its quarterly report on Form 10-Q. Jed Latkin, Chief Executive Officer, and Erika Gibson, Director, Finance and Administrat...
Navidea Biopharmaceuticals Wins Dismissal of Platinum Litigation
DUBLIN, Ohio--(BUSINESS WIRE)-- On October 31, 2018, Judge Valerie Caproni of the United States District Court for the Southern District of New York entered an Opinion and Order, as well as a Judgment, dismissing all claims raised by Platinum-Montaur Life Sciences LLC (“Platinum-Montaur”) in its litigation against Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”). Platinum’s claims arose from a note and loan agreement entered on July 25, 2012 (the “Note”), under which Navidea borrowed certain sums fro...
Navidea Biopharmaceuticals Receives Acceptance Letter from NYSE Americ...
DUBLIN, Ohio--(BUSINESS WIRE)-- As previously disclosed, on August 14, 2018, Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, received a notification (the “Deficiency Letter”) from the NYSE American LLC (the “NYSE American”) stating that Navidea was not in compliance with Section 1003(a)(ii) and Section 1003(f)(v) of the NYSE American continued listing standards, which relate to stockholders’ equity and...
Navidea Biopharmaceuticals to Present Data on the Manocept Platform at...
DUBLIN, Ohio--(BUSINESS WIRE)-- Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, announced today the company will present a poster detailing results from the Company’s clinical trials assessing Tc 99m tilmanocept in rheumatoid arthritis (RA) at the American College of Rheumatology (ACR) 2018 Annual Meeting, being held October 19-24, 2018 in Chicago, Illinois. Tc 99m tilmanocept is the first product deve...
Navidea Biopharmaceuticals to Present at the 2018 BIO Investor Forum
DUBLIN, Ohio--(BUSINESS WIRE)-- Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, announced today that its Chief Executive Officer, Jed Latkin, will present a corporate overview of the Company at the 2018 BIO Investor Forum, being held October 17-18, 2018 in San Francisco, California. Conference Presentation Details: Where: ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.